Using genetics
to understand
glaucoma risk

close up eye

Our story

Seonix was founded by leading ophthalmologists and researchers who understand the impact of glaucoma vision loss on peoples’ lives. Building on many years of research, and access to some of the world’s largest glaucoma datasets, they identified thousands of genetic variants that increase an individual’s risk of glaucoma and developed this into a genetic risk score.

Seonix is now a growing company committed to bringing the benefits of improved genetic risk prediction information to eye health professionals, individuals, and researchers.

Our mission is to reduce blinding eye disease through the development of advanced techniques for clinical risk prediction.

Our leadership team

Seonix’s leadership comprises clinicians, researchers and industry experts who firmly believe there is a better way to identify individuals at risk of glaucoma so they can be diagnosed sooner.

Nick Haan
PhD
Chief Executive Officer
An experienced leader in the genomic diagnostics industry, Nick was a co-founder and CEO of BlueGnome, acquired by US sequencing giant Illumina in 2012.
Johnathon Matthews
LLB Bec BCom GAICD
Co-Founder
Extensive management experience in the medical devices industry. Mr Matthews also acts as a director of Austofix and BiomeBank.
Jamie Craig
MBBS DPhil FRANZCO
Co-Founder
Professor of Ophthalmology at Flinders University, Consultant Ophthalmologist and glaucoma sub-specialist, and leader of two of the world’s largest studies of glaucoma genetics.
Stuart MacGregor
PhD
Co-Founder
Professor of Statistical Genetics at the QIMR Berghofer Medical Research Institute, and international authority in glaucoma genetic risk prediction.
Alex Hewitt
MBBS PhD FRANZCO
Co-Founder
Professor of Ophthalmology at the University of Tasmania and the Centre for Eye Research Australia, and Board Member of the Ophthalmic Research Institute of Australia.
Owen Siggs
MD DPhil
Co-Founder
Snow Fellow & Faculty Member at the Garvan Institute of Medical Research, with >15 years experience in academic genetic research and clinical medicine.
Sinead O'Connell
PhD
Commercialisation Manager
Experienced in academic commercialisation ventures through industry connections and intellectual property management. Dr O’Connell is a director of two academic spinout companies.